U.S. markets close in 6 hours 24 minutes
  • S&P 500

    +1.67 (+0.04%)
  • Dow 30

    -11.91 (-0.03%)
  • Nasdaq

    +23.18 (+0.16%)
  • Russell 2000

    -6.07 (-0.26%)
  • Crude Oil

    -0.03 (-0.04%)
  • Gold

    +3.60 (+0.19%)
  • Silver

    +0.21 (+0.77%)

    -0.0016 (-0.13%)
  • 10-Yr Bond

    -0.0080 (-0.53%)

    +0.0026 (+0.19%)

    -0.1260 (-0.11%)

    -933.86 (-2.32%)
  • CMC Crypto 200

    -19.30 (-1.94%)
  • FTSE 100

    +11.28 (+0.16%)
  • Nikkei 225

    -150.29 (-0.51%)

Can You Imagine How Elated AtriCure's (NASDAQ:ATRC) Shareholders Feel About Its 427% Share Price Gain?

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

For many, the main point of investing in the stock market is to achieve spectacular returns. And we've seen some truly amazing gains over the years. To wit, the AtriCure, Inc. (NASDAQ:ATRC) share price has soared 427% over five years. This just goes to show the value creation that some businesses can achieve. On top of that, the share price is up 31% in about a quarter. The company reported its financial results recently; you can catch up on the latest numbers by reading our company report.

View our latest analysis for AtriCure

Given that AtriCure didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Shareholders of unprofitable companies usually expect strong revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

In the last 5 years AtriCure saw its revenue grow at 9.3% per year. That's a pretty good long term growth rate. However, the share price gain of 39% during the period is considerably stronger. It might not be cheap but a (long-term) growth stock like this is usually well worth taking a closer look at.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).


We like that insiders have been buying shares in the last twelve months. Even so, future earnings will be far more important to whether current shareholders make money. This free report showing analyst forecasts should help you form a view on AtriCure

A Different Perspective

It's good to see that AtriCure has rewarded shareholders with a total shareholder return of 76% in the last twelve months. Since the one-year TSR is better than the five-year TSR (the latter coming in at 39% per year), it would seem that the stock's performance has improved in recent times. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. It's always interesting to track share price performance over the longer term. But to understand AtriCure better, we need to consider many other factors. Case in point: We've spotted 3 warning signs for AtriCure you should be aware of.

AtriCure is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.